Global Pediatric Vaccines Market By Type, By Technology, By Indication: Global Opportunity Analysis and Industry Forecast, 2021-2031

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL PEDIATRIC VACCINES MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Monovalent
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Multivalent
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country

CHAPTER 5: GLOBAL PEDIATRIC VACCINES MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Live Attenuated Vaccines
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Inactivated Vaccines
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Toxoid Vaccines
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
5.5 Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market share analysis by country

CHAPTER 6: GLOBAL PEDIATRIC VACCINES MARKET, BY INDICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Varicella
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Diphtheria, Pertussis and Tetanus
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Influenza
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
6.5 Human Papilloma Virus
6.5.1 Key market trends, growth factors and opportunities
6.5.2 Market size and forecast, by region
6.5.3 Market share analysis by country
6.6 Measles, Mumps and Rubella
6.6.1 Key market trends, growth factors and opportunities
6.6.2 Market size and forecast, by region
6.6.3 Market share analysis by country
6.7 Meningococcal Disease
6.7.1 Key market trends, growth factors and opportunities
6.7.2 Market size and forecast, by region
6.7.3 Market share analysis by country
6.8 Pneumococcal Disease
6.8.1 Key market trends, growth factors and opportunities
6.8.2 Market size and forecast, by region
6.8.3 Market share analysis by country
6.9 Polio
6.9.1 Key market trends, growth factors and opportunities
6.9.2 Market size and forecast, by region
6.9.3 Market share analysis by country
7.0 Rotavirus
7.0.1 Key market trends, growth factors and opportunities
7.0.2 Market size and forecast, by region
7.0.3 Market share analysis by country
7.1 Other Indications
7.1.1 Key market trends, growth factors and opportunities
7.1.2 Market size and forecast, by region
7.1.3 Market share analysis by country

CHAPTER 7: GLOBAL PEDIATRIC VACCINES MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Technology
7.2.4 North America Market size and forecast, by Indication
7.2.5 North America Market size and forecast, by country
7.2.5.1 U. S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Type
7.2.5.1.3 Market size and forecast, by Technology
7.2.5.1.4 Market size and forecast, by Indication
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Type
7.2.5.2.3 Market size and forecast, by Technology
7.2.5.2.4 Market size and forecast, by Indication
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Type
7.2.5.3.3 Market size and forecast, by Technology
7.2.5.3.4 Market size and forecast, by Indication
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Technology
7.3.4 Europe Market size and forecast, by Indication
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Type
7.3.5.1.3 Market size and forecast, by Technology
7.3.5.1.4 Market size and forecast, by Indication
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Type
7.3.5.2.3 Market size and forecast, by Technology
7.3.5.2.4 Market size and forecast, by Indication
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Type
7.3.5.3.3 Market size and forecast, by Technology
7.3.5.3.4 Market size and forecast, by Indication
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Type
7.3.5.4.3 Market size and forecast, by Technology
7.3.5.4.4 Market size and forecast, by Indication
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Type
7.3.5.5.3 Market size and forecast, by Technology
7.3.5.5.4 Market size and forecast, by Indication
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Type
7.3.5.6.3 Market size and forecast, by Technology
7.3.5.6.4 Market size and forecast, by Indication
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Technology
7.4.4 Asia-Pacific Market size and forecast, by Indication
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Type
7.4.5.1.3 Market size and forecast, by Technology
7.4.5.1.4 Market size and forecast, by Indication
7.4.5.2 Japan
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Type
7.4.5.2.3 Market size and forecast, by Technology
7.4.5.2.4 Market size and forecast, by Indication
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Type
7.4.5.3.3 Market size and forecast, by Technology
7.4.5.3.4 Market size and forecast, by Indication
7.4.5.4 Australia
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Type
7.4.5.4.3 Market size and forecast, by Technology
7.4.5.4.4 Market size and forecast, by Indication
7.4.5.5 South Korea
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Type
7.4.5.5.3 Market size and forecast, by Technology
7.4.5.5.4 Market size and forecast, by Indication
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Type
7.4.5.6.3 Market size and forecast, by Technology
7.4.5.6.4 Market size and forecast, by Indication
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Technology
7.5.4 LAMEA Market size and forecast, by Indication
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Type
7.5.5.1.3 Market size and forecast, by Technology
7.5.5.1.4 Market size and forecast, by Indication
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Type
7.5.5.2.3 Market size and forecast, by Technology
7.5.5.2.4 Market size and forecast, by Indication
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Type
7.5.5.3.3 Market size and forecast, by Technology
7.5.5.3.4 Market size and forecast, by Indication
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Type
7.5.5.4.3 Market size and forecast, by Technology
7.5.5.4.4 Market size and forecast, by Indication

CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES
9.1 AstraZeneca Plc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 CSL Limited
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Emergent BioSolutions Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 GlaxoSmithKline plc.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Johnson & Johnson
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Novavax, Inc.
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Pfizer Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Sanofi Aventis
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Serum Institute of India Pvt. Ltd.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

Executive Summary

According to this report, titled, 'Global Pediatric Vaccines Market,' the global pediatric vaccines market was valued at $21.4 billion in 2021, and is estimated to reach $36.4 billion by 2031, growing at a CAGR of 5.4% from 2022 to 2031.

The pediatric vaccines market is likely to experience a significant growth rate of 5.4% from 2022-2031 owing to increasing market demand for pediatric vaccine product from healthcare sector.

Pediatric vaccines are the vaccines given to the children as a kind of protection against dangerous, frequently fatal infections. Pediatric vaccines stimulate a child's immune response to a particular disease, which helps the child's immune system fight infections more effectively. Pediatric vaccines include pneumococcal vaccine, DTP vaccine, rotavirus vaccine, MMR vaccine, polio vaccine, influenza vaccine, hepatitis B vaccine, Hib vaccine, and meningococcal vaccine. Before becoming available to the general public, all vaccinations must pass stringent safety evaluations, including clinical trials. Only vaccinations that pass strict quality and safety requirements will be registered and distributed by nations.

Major factors driving the growth of the pediatric vaccines market include increase in focus on improving primary healthcare, increase in investment of government as well as non-government organization and increasing the accessibility of vaccines by making them available at affordable rates at government institutions. In addition, surge in immunization program across the globe drive the growth of the market. For instance, MenA vaccine has been approved and implemented in almost 22 countries and is a part of routine immunization in 8 countries of the meningitis belt. According to CDC, the Food and Drug Administration (FDA) licensed 11 vaccines for use in the U.S. to help protect against diphtheria and tetanus. Moreover, increase in R&D activities to develop new vaccine further boost the market growth. For instance, GSK has increased investments in R&D and new products to deliver future growth. In addition, Sanofi received an approval in April, 2020 for Meningococcal ACYW Conjugate vaccine.

Moreover, in June, 2021, Merck and Sanofi received an approval for six-in-one pediatric combination vaccine in the U.S. However, the high cost of vaccine refrigeration and lack of accessibility to pediatric medications in emerging nations due to inadequate healthcare infrastructure and less awareness are the factors which is anticipated to impede market expansion. Conversely, increase in childbirths associated with high risk of infection due to poor infant immunity, high risk of meningitis, measles, rotavirus, pneumococcal disease, and growth in awareness toward immunization are some of the factors that provide lucrative opportunities for the vaccines across the emerging markets. Moreover, the market also offers growth opportunities to the key players in the market. As the development of new vaccines to treat pediatric disorder, there is an estimated a rise in demand for the pediatric vaccine products during the forecast period.

The global pediatric vaccines market is segmented on the basis of type, technology, indication, and region. As per type, the market is categorized into monovalent and multivalent. On the basis of technology, it is bifurcated into live attenuated vaccines, inactivated vaccines, toxoid vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines. On the basis of indication, it is segmented into varicella, diphtheria, pertussis & tetanus, influenza, human papilloma virus, measles, mumps & rubella, meningococcal disease, pneumococcal disease, polio, rotavirus, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

The key players profiled in the study includes the Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, AstraZeneca plc. GlaxoSmithKline plc., Sanofi Aventis, Merck & Co., Inc., Emergent BioSolutions Inc., CSL Limited, and Novavax, Inc. The players in the market have been actively engaged in the adoption strategy such as product approval, acquisition, product launch and collaboration to remain competitive and gain advantage over the competitors in the market. For instance, In October 2021, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) have issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older. In addition, In June 2022, Merck announced that the U.S. Food and Drug Administration (FDA) has approved VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children.

Key Market Insights

• By type, the monovalent segment was the highest revenue contributor to the market with a CAGR of 5.0% during the forecast period and is estimated to reach $ 28,297.2 million by 2031.
• Based on technology, the subunit, recombinant, polysaccharide, and conjugate vaccines segment dominates the market in 2021, and is expected to continue this trend during the forecast period.
• Based on indication, the pneumococcal segment dominates the market in 2021, and is expected to continue this trend during the forecast period.
• Based on region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR of 6.9% during the forecast period'

According to this report, titled, 'Travel Insurance Market,' the travel insurance market was valued at $14.2 billion in 2021, and is estimated to reach $124.8 billion by 2031, growing at a CAGR of 24.7% from 2022 to 2031.
'According to this report, titled, 'Lower Extremity Devices Market,' the lower extremity devices market was valued at $664.56 million in 2021, and is estimated to reach $1,285.57 millionby 2031, growing at a CAGR of 6.8% from 2022 to 2031.

Lower extremity devices are the external devices that are attached or applied to a lower limb to enhance the function by offering support, regulating mobility, easing discomfort, addressing abnormalities, and preventing the deformity progression. Knee orthotic devices are used to treat the ligament damage, multiple sclerosis, jumper’s knee, hyperextension, and instability whereas ankle and foot orthotic devices are used in the treatment of drop foot or dorsiflexion weakness, peroneal nerve injury, diabetes, multiple sclerosis, and osteoarthritis. The lower extremity device is made up of powered, external orthotic parts that are controlled by controllers and/or sensors. Movement of one or more lower extremity joints is made easier by the device. These devices are used in trauma, fractures, osteoporosis, preventative care, amputation, cerebral palsy and stroke.

Key factors driving the growth of the lower extremity device market include increase in the number of people suffering from bone degenerative diseases. Osteoporosis, bone fractures, stress fractures, bone cancer, scoliosis, osteoarthritis are the most common bone degenerative diseases. The risk of osteoporosis in young people has increased by the modern lifestyle, which include inadequate calcium intake, little sun exposure leading to vitamin D deficiency, lack of exercise, and bad habits like smoking and alcohol consumption. In addition, road accidents is one of the major factors contributing in rise of bone related disorders. Most frequent broken bones after car accidents are likely to be pelvic bone fractures. Although fibula and femur are typically sturdy bones, they are also susceptible to breaking if accidents occur into a person's leg brutally. High incidences of the road accidents significantly drive the market growth. High prevalence of orthopedic diseases, increase in adoption of extremity devices and strong presence of key players and availability of developed healthcare infrastructure along with technological advanced systems further contributes towards the market growth. Development of advanced and reliable lower extremity device, coupled with the increase in awareness for orthotics care and better healthcare services is expected to propel the lower extremity device market.

The market also offers growth opportunities to the key players in the market. Developing economies in Asia-Pacific and LAMEA offer lucrative potential for market growth. Rise in the investments from developed nations in Asia-Pacific, together with an increase in awareness regrading orthopedic diseases, will have a beneficial impact on the market. In addition, rise in traffic accidents and sports-related injuries which requires the lower extremity devices this has led to provide the lucrative opportunity for the market growth. Thus, growing opportunity in emerging markets propel the lower extremity market growth.

The lower extremity device market is segmented into product, application, end user, and region. On the basis of product, the market is categorized into knee orthotics, foot & ankle orthotics, and hip orthotics. On the basis of application, it is categorized into trauma & fracture and others. On the basis of end user, it is segmented into hospital & surgical centers, retail Pharmacies, and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study include 3M, Bauerfeind AG, Enovis, Essity AB, DeRoyal Industries, Inc, Orthofix Medical Inc., (Breg Inc.), Össur HF, Otto Bock HealthCare GmbH, Thuasne group and Trulife. The players in the market have been actively engaged in the adoption various strategies such as product launch and partnership to remain competitive and gain advantage over the competitors in the market. For instance, in June 2022, DJO, which is now Enovis, launched DonJoy X-ROM Post-Op Knee Brace. Featuring DonJoy’s most advanced range of motion (ROM) protection and improved user-friendly design for faster, easier application and adjustment, the X-ROM brace helps patients recover from ACL repair and other knee surgeries with improved confidence, comfort and stability.

Key Market Insights

• By product, the knee orthotics segment was the largest revenue contributor to the market in 2021 and is estimated to reach $746.18 million by 2031, with a highest CAGR.
• By application, the trauma & fracture segment dominated the global market in 2021. However, the others segment is expected to be the fastest-growing segment with a highest CAGR during the forecast period.
• Based on end user, the hospital & surgical segment was the highest revenue contributor to the market in 2021. However, the others segment is expected to be the fastest-growing segment with a highest CAGR during the forecast period.
• Based on region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period

Companies Mentioned

• Astrazeneca PLC.
• Csl Limited
• Emergent Biosolutions Inc.
• GlaxoSmithKline PLC.
• Johnson & Johnson
• Merck & Co. Inc.
• Novavax, Inc.
• Pfizer Inc.
• Sanofi Aventis
• Serum Institute of India Pvt. Ltd.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

• Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
• Scientific and technical writings for product information and related preemptions
• Regional government and statistical databases for macro analysis
• Authentic news articles and other related releases for market evaluation
• Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.